Progression of renal fibrosis: The underestimated role of endothelial alterations

Fibrogenesis and Tissue Repair

Volumn 5, Issue SUPPL.1, 2012, Pages

  Guerrot, Dominique ^a,b,c   Dussaule, Jean Claude ^a,b   Kavvadas, Panagiotis ^a   Boffa, Jean Jacques ^a,b   Chadjichristos, Christos E ^a,b   Chatziantoniou, Christos ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1 ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY PARENCHYMA; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENOVASCULAR DISEASE; SHEAR STRESS;

EID: 84881016724     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-5-S1-S15     Document Type: Article

References (51)

1. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006, 291:H985-1002. 10.1152/ajpheart.00292.2006, 16632549.
2. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
3. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314-1319. 10.1161/01.CIR.91.5.1314, 7867167.
4. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens 2005, (19 Suppl 1):S21-25.
5. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease: Clin Chim Acta. Netherlands 2006, 33-47.
6. Rabelink TJ, de Boer HC, van Zonneveld AJ. Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol 2010, 6:404-414. 10.1038/nrneph.2010.65, 20498676.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305. 10.1056/NEJMoa041031, 15385656.
8. Zoccali C. Endothelial dysfunction in CKD: a new player in town?. Nephrol Dial Transplant 2008,
9. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004, 15:538-548. 10.1097/01.ASN.0000111744.00916.E6, 14978155.
10. Cooke JP. Asymmetrical dimethylarginine: the Uber marker?. Circulation 2004, 109:1813-1818. 10.1161/01.CIR.0000126823.07732.D5, 15096461.
11. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003, 18:892-898. 10.1093/ndt/gfg080, 12686661.
12. Mihout F, Shweke N, Bige N, et al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol 2011, 223:37-45. 10.1002/path.2769, 20845411.
13. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005, 16:2456-2461. 10.1681/ASN.2005020179, 15930091.
14. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313. 10.1152/physrev.00044.2005, 17237347.
15. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999, 99:2185-2191. 10.1161/01.CIR.99.16.2185, 10217661.
16. Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 2010, 6:667-678. 10.1038/nrneph.2010.124, 20877304.
17. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000, 58:2351-2366. 10.1046/j.1523-1755.2000.00419.x, 11115069.
18. Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT. The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem 2003, 278:40296-40304. 10.1074/jbc.M302560200, 12885785.
19. Brodsky SV, Yamamoto T, Tada T, et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 2002, 282:F1140-1149.
20. Choi YJ, Chakraborty S, Nguyen V, et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 2000, 31:1491-1497. 10.1053/hupa.2000.20373, 11150374.
21. Kwon O, Hong SM, Sutton TA, Temm CJ. Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol 2008, 295:F351-359. 10.1152/ajprenal.90276.2008, 2519188, 18562634.
22. Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 2010, 25:1079-1087. 10.1093/ndt/gfp605, 2902859, 19934087.
23. Ochodnický P, Henning RH, Buikema HJ, de Zeeuw D, Provoost AP, van Dokkum RP. Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. Am J Physiol Renal Physiol 2010, 298:F625-633. 10.1152/ajprenal.00289.2009, 20007352.
24. Bojakowski K, Abramczyk P, Bojakowska M, Zwolinska A, Przybylski J, Gaciong Z. Fucoidan improves the renal blood flow in the early stage of renal ischemia/reperfusion injury in the rat. J Physiol Pharmacol 2001, 52:137-143.
25. Kato N, Yuzawa Y, Kosugi T, et al. The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. J Am Soc Nephrol 2009, 20:1565-1576. 10.1681/ASN.2008090957, 2709679, 19443639.
26. De Vriese AS, Endlich K, Elger M, et al. The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 1999, 10:2510-2517.
27. Asgeirsdóttir SA, Zwiers PJ, Morselt HW, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol 2008, 294:F554-561. 10.1152/ajprenal.00391.2007, 18160627.
28. Kelly KJ, Williams WW, Colvin RB, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994, 91:812-816. 10.1073/pnas.91.2.812, 43039, 7904759.
29. Kelly KJ, Williams WW, Colvin RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996, 97:1056-1063. 10.1172/JCI118498, 507153, 8613529.
30. Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res 2004, 62:228-232. 10.1016/j.cardiores.2003.11.013, 15094343.
31. Harris AL. Connexin channel permeability to cytoplasmic molecules. Prog Biophys Mol Biol 2007, 94:120-143. 10.1016/j.pbiomolbio.2007.03.011, 1995164, 17470375.
32. Scheckenbach KE, Crespin S, Kwak BR, Chanson M. Connexin Channel-Dependent Signaling Pathways in Inflammation. J Vasc Res Basel 2010, 91-103.
33. Chadjichristos CE, Scheckenbach KE, van Veen TA, et al. Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation 2010, 121:123-131. 10.1161/CIRCULATIONAHA.109.867176, 20026782.
34. Veliz LP, Gonzalez FG, Duling BR, Saez JC, Boric MP. Functional role of gap junctions in cytokine-induced leukocyte adhesion to endothelium in vivo. Am J Physiol Heart Circ Physiol 2008, 295:H1056-H1066. 10.1152/ajpheart.00266.2008, 2544495, 18599597.
35. Parthasarathi K, Ichimura H, Monma E, et al. Connexin 43 mediates spread of Ca2+-dependent proinflammatory responses in lung capillaries. J Clin Invest 2006, 116:2193-2200. 10.1172/JCI26605, 1518791, 16878174.
36. Chadjichristos CE, Morel S, Derouette JP, et al. Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells: Circ Res. United States 2008, 653-660.
37. Dussaule JC, Guerrot D, Huby AC, et al. The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol 2011,
38. Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair 2011, 4:11. 10.1186/1755-1536-4-11, 3079627, 21470408.
39. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J Clin Invest 2011, 121:468-474. 10.1172/JCI44595, 3026733, 21370523.
40. Piera-Velazquez S, Li Z, Jimenez SA. Role of Endothelial-Mesenchymal Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders. Am J Pathol 2011, 179:1074-1080. 10.1016/j.ajpath.2011.06.001, 21763673.
41. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961. 10.1038/nm1613, 17660828.
42. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 2009, 175:1371-1373. 10.2353/ajpath.2009.090698, 2751533, 19729485.
43. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008, 19:2282-2287. 10.1681/ASN.2008050513, 2588112, 18987304.
44. Li J, Qu X, Yao J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:2612-2624. 10.2337/db09-1631, 3279546, 20682692.
45. Basile DP, Friedrich JL, Spahic J, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol 2011, 300:F721-733. 10.1152/ajprenal.00546.2010, 3064142, 21123492.
46. Melo-Filho NM, Belmiro CL, Gonçalves RG, et al. Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event?. Am J Physiol Renal Physiol 2010, 299:F1299-1307. 10.1152/ajprenal.00217.2010, 20861075.
47. Choi DE, Jeong JY, Lim BJ, et al. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 2009, 297:F362-370. 10.1152/ajprenal.90609.2008, 19474186.
48. Asgeirsdóttir SA, Kamps JA, Bakker HI, et al. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol 2007, 72:121-131. 10.1124/mol.107.034140, 17452496.
49. Masuda Y, Shimizu A, Mori T, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001, 159:599-608. 10.1016/S0002-9440(10)61731-2, 1850560, 11485918.
50. Chade AR, Zhu XY, Krier JD, et al. Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells 2010, 28:1039-1047. 10.1002/stem.426, 2958683, 20506499.
51. Stokman G, Stroo I, Claessen N, Teske GJ, Florquin S, Leemans JC. SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2010, 25:3852-3859. 10.1093/ndt/gfq311, 20519232.